Literature DB >> 17211670

[Enteropathy type T-cell lymphomas: pathology and pathogenesis].

A Zettl1, T Rüdiger, H K Müller-Hermelink.   

Abstract

Enteropathy type T-cell lymphomas (ETL) are the most frequent T-cell lymphomas arising in the gastrointestinal tract. Commonly, the neoplasm is clinically associated with symptoms of malabsorption, and it frequently manifests as a spontaneous bowel perforation. Among ETL, two types can be distinguished by morphology, immunophenotype and, possibly, by pathogenesis. A total of 80% of ETL are characterized by a close association with celiac disease, pleomorphic cytomorphology and the rare expression of CD8 and CD56. In contrast, 20% of ETL show a monomorphic small to medium size cytomorphology and frequent expression of CD8 and CD56, an association with celiac disease is rare in the latter cases. Genetically, ETL is characterized by frequent and recurrent chromosomal gains of 9q33-q34.

Entities:  

Mesh:

Year:  2007        PMID: 17211670     DOI: 10.1007/s00292-006-0886-2

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  13 in total

1.  Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations.

Authors:  Andreas Zettl; Thomas Rüdiger; Maria-Anette Konrad; Andreas Chott; Ingrid Simonitsch-Klupp; Ruth Sonnen; Hans Konrad Müller-Hermelink; German Ott
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

2.  Classification of intestinal T-cell neoplasms and their differential diagnosis.

Authors:  A Chott; M Vesely; I Simonitsch; I Mosberger; H Hanak
Journal:  Am J Clin Pathol       Date:  1999-01       Impact factor: 2.493

3.  Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma.

Authors:  S Daum; M Hummel; D Weiss; M Peters; B Wiedenmann; F Schäper; H Stein; E O Riecken; H Foss
Journal:  Digestion       Date:  2000       Impact factor: 3.216

4.  Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.

Authors:  J Gale; P D Simmonds; G M Mead; J W Sweetenham; D H Wright
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

5.  Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group.

Authors:  C Cellier; E Delabesse; C Helmer; N Patey; C Matuchansky; B Jabri; E Macintyre; N Cerf-Bensussan; N Brousse
Journal:  Lancet       Date:  2000-07-15       Impact factor: 79.321

6.  Malignant histiocytosis of the intestine: a T-cell lymphoma.

Authors:  P G Isaacson; N T O'Connor; J Spencer; D H Bevan; C E Connolly; N Kirkham; D J Pollock; J S Wainscoat; H Stein; D Y Mason
Journal:  Lancet       Date:  1985-09-28       Impact factor: 79.321

7.  Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue.

Authors:  Virginie Verkarre; Serge-Pierrick Romana; Christophe Cellier; Vahid Asnafi; Jean-Jacques Mention; Ullah Barbe; Sylvie Nusbaum; Olivier Hermine; Elizabeth Macintyre; Nicole Brousse; Nadine Cerf-Bensussan; Isabelle Radford-Weiss
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

8.  Malignant histiocytosis of the intestine. Its relationship to malabsorption and ulcerative jejunitis.

Authors:  P Isaacson; D H Wright
Journal:  Hum Pathol       Date:  1978-11       Impact factor: 3.466

9.  Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology.

Authors:  A Chott; W Haedicke; I Mosberger; M Födinger; K Winkler; C Mannhalter; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Refractory coeliac sprue is a diffuse gastrointestinal disease.

Authors:  V Verkarre; V Asnafi; T Lecomte; N Patey Mariaud-de Serre; M Leborgne; E Grosdidier; C Le Bihan; E Macintyre; C Cellier; N Cerf-Bensussan; N Brousse
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

View more
  1 in total

Review 1.  [In situ lymphoma and other early stage malignant non-Hodgkin lymphomas].

Authors:  L Quintanilla-Martínez; P Adam; F Fend
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.